Pfizer Inc banner

Pfizer Inc
SGO:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
SGO:PFE
Watchlist
Price: 49.19 USD -0.36% Market Closed
Market Cap: $165.2B

Relative Value

The Relative Value of one PFE stock under the Base Case scenario is 64.34 USD. Compared to the current market price of 49.19 USD, Pfizer Inc is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PFE Relative Value
Base Case
64.34 USD
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

PFE Competitors Multiples
Pfizer Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Pfizer Inc
SGO:PFE
158B USD 2.5 20.3 7.5 10.1
US
Eli Lilly and Co
NYSE:LLY
960.1B USD 14.7 46.5 31.4 33.4
US
Johnson & Johnson
NYSE:JNJ
579.4B USD 6.2 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.2B CHF 4.6 29.9 12.6 14.8
UK
AstraZeneca PLC
LSE:AZN
228.3B GBP 5.5 33.7 16 23.5
CH
Novartis AG
SIX:NOVN
235.6B CHF 5.4 21.7 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
295.4B USD 4.5 16.2 10.1 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.7 11.4
US
Bristol-Myers Squibb Co
NYSE:BMY
122.2B USD 2.5 17.3 6.8 8.7
UK
GSK plc
XETRA:GS71
100.9B EUR 2.7 15.4 7.8 11.1
P/E Multiple
Earnings Growth PEG
US
Pfizer Inc
SGO:PFE
Average P/E: 23.6
20.3
26%
0.8
US
Eli Lilly and Co
NYSE:LLY
46.5
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
29.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
33.7
38%
0.9
CH
Novartis AG
SIX:NOVN
21.7
15%
1.4
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
7%
1.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
17%
1
UK
GSK plc
XETRA:GS71
15.4
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Pfizer Inc
SGO:PFE
Average EV/EBITDA: 42.1
7.5
-4%
N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
16
10%
1.6
CH
Novartis AG
SIX:NOVN
13.4
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.1
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
7%
1.4
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
UK
GSK plc
XETRA:GS71
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Pfizer Inc
SGO:PFE
Average EV/EBIT: 90.5
10.1
-1%
N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
23.5
23%
1
CH
Novartis AG
SIX:NOVN
17.2
12%
1.4
US
Merck & Co Inc
NYSE:MRK
11.8
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
8%
1.4
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-6%
N/A
UK
GSK plc
XETRA:GS71
11.1
12%
0.9